Leonabio Inc stock is traded at $3.73, with a volume of 25,486. It is down -3.87% in the last 24 hours and down -41.99% over the past month. LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Previous Close:
$3.88
Open:
$3.90
24h Volume:
25,486
Relative Volume:
0.45
Market Cap:
$35.14M
Revenue:
-
Net Income/Loss:
-$129.41M
P/E Ratio:
-
EPS:
-$24.09
Net Cash Flow:
-$51.97M
1W Performance:
-15.52%
1M Performance:
-41.99%
6M Performance:
-63.86%
1Y Performance:
0.00%
1-Day Range:
$3.62$3.92
1-Week Range:
$3.60$4.80
52-Week Range:
$2.21$14.21
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio IncSector
HealthcareIndustry
BiotechnologyPhone
(425) 620-8501Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS